Refractory serositis in Gorham-Stout syndrome

Orphanet J Rare Dis. 2022 Apr 4;17(1):152. doi: 10.1186/s13023-022-02307-8.

Abstract

Background: Gorham-Stout syndrome (GSS) is a rare disorder with various presentations and unpredictable prognoses. Previous understandings of GSS mainly focused on progressive bone destruction, while we identified a group of GSS patients with serous effusion as the first symptom. This study aimed to investigate the clinical characteristics of patients with GSS having serous effusion as the first symptom.

Methods: Patients diagnosed with GSS were identified through the Peking Union Medical College Hospital Medical Record System. The demographic, clinical, laboratory, and imaging data were collected. Patients who first presented with serous effusion were recruited into the serous group, while those with bone destruction were recruited into the bone group.

Results: Of the 23 patients with GSS enrolled, 13 were in the bone group and 10 in the serous group. The median disease duration was shorter and exercise tolerance was lower in the serous group. Despite less frequent bone pain in the serous group, the frequency of bone involvement was similar to that in the bone group. Patients in the serous group had higher rates of bilateral pleural effusion and multiple serous effusion. However, serous effusion also developed with disease progression in the bone group. Of the 17 patients treated with bisphosphonates, 14 reached bone-stable state. However, 5 out of 10 patients with serous effusion still had refractory effusions after bisphosphonates treatment. Three patients received sirolimus treatment, with an improvement in serous effusion. Seventeen patients were followed up; three patients died, two in the bone group and one in the serous group.

Conclusions: This study discovered that GSS could first be presented with serous effusion. We believe that this may be a new phenotype of the disease. Sirolimus might help in controlling serous effusion and improving prognosis.

Keywords: Bisphosphonates; Clinical characteristics; Gorham–Stout syndrome; Lymphatic malformations; Prognosis; Serous effusion; Sirolimus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diphosphonates / therapeutic use
  • Humans
  • Osteolysis, Essential* / drug therapy
  • Prognosis
  • Serositis* / drug therapy
  • Sirolimus / therapeutic use

Substances

  • Diphosphonates
  • Sirolimus